Supplementary information

TABLE S1 IPF history and relevant baseline characteristics by treatment group in patients treated with and without background therapy (randomised population)

	Patients with background therapy			Patients without background therapy		
	Placebo	**SAR156597 Q2W**	**SAR156597 QW**	**Placebo**	**SAR156597 Q2W**	**SAR156597 QW**
Time since IPF diagnosis, years						
N	56	55	56	54	54	52
Mean (SD)	1.9 (1.2)	2.0 (1.3)	2.0 (1.2)	1.8 (1.5)	1.7 (1.4)	1.7 (1.3)
Median (range)	1.8 (0.1–5.0)	1.7 (0.3–4.8)	1.8 (0.4–5.0)	1.6 (0.1–4.9)	1.4 (0.1–4.8)	1.4 (0.1–4.5)
Time since first IPF symptoms, years						
N	56	55	56	54	54	52
Mean (SD)	3.1 (2.0)	4.1 (2.6)	3.6 (2.0)	3.3 (2.4)	3.0 (1.8)	3.1 (2.0)
Median (range)	2.7 (0.8–12.2)	3.7 (0.9–16.2)	3.6 (0.6–10.2)	3.1 (0.1–11.1)	2.6 (0.3–7.9)	2.6 (0.4–8.2)
Any acute exacerbation within the past 12 months prior to enrolment, n (%)						
N	56	55	56	54	54	52
Yes	1 (1.8)	1 (1.8)	2 (3.6)	5 (9.3)	5 (9.3)	3 (5.8)
No	55 (98.2)	54 (98.2)	54 (96.4)	49 (90.7)	49 (90.7)	49 (94.2)
Family IPF history, n (%)						
N	56	54	56	54	54	52
Yes	6 (10.7)	2 (3.7)	5 (8.9)	4 (7.4)	4 (7.4)	5 (9.6)
No	44 (78.6)	49 (90.7)	47 (83.9)	49 (90.7)	50 (92.6)	47 (90.4)

Unknown	6 (10.7)	3 (5.6)	4 (7.1)	1 (1.9)	0	0
Supplemental oxygen use, n (%)						
N	56	55	56	54	54	52
Yes	12 (21.4)	7 (12.7)	10 (17.9)	5 (9.3)	5 (9.3)	6 (11.5)
No	44 (78.6)	48 (87.3)	46 (82.1)	49 (90.7)	49 (90.7)	46 (88.5)

IPF: idiopathic pulmonary fibrosis; QW: once every week; Q2W: once every 2 weeks; SD: standard deviation.

TABLE S2 Summary of TEAEs in patients treated with and without background therapy (safety population)

	Patients with background therapy			Patients without background therapy		
	Placebo (N=55)	**SAR156597 Q2W (N=54)**	**SAR156597 QW (N=56)**	**Placebo (N=54)**	**SAR156597 Q2W (N=54)**	**SAR156597 QW (N=52)**
Patients with any TEAE, n (%)	52 (94.5)	54 (100)	56 (100)	47 (87.0)	48 (88.9)	44 (84.6)
Most frequently reported TEAEs,[#] n (%)						
IPF	11 (20.0)	13 (24.1)	19 (33.9)	8 (14.8)	6 (11.1)	11 (21.2)
Diarrhoea	9 (16.4)	18 (33.3)	9 (16.1)	7 (13.0)	5 (9.3)	3 (5.8)
Cough	9 (16.4)	12 (22.2)	11 (19.6)	3 (5.6)	10 (18.5)	7 (13.5)
Viral upper RTI	8 (14.5)	9 (16.7)	7 (12.5)	8 (14.8)	9 (16.7)	5 (9.6)
Dyspnoea	6 (10.9)	8 (14.8)	8 (14.3)	5 (9.3)	2 (3.7)	5 (9.6)
Bronchitis	5 (9.1)	11 (20.4)	5 (8.9)	8 (14.8)	7 (13.0)	6 (11.5)
Nausea	7 (12.7)	6 (11.1)	7 (12.5)	2 (3.7)	3 (5.6)	2 (3.8)
Weight decreased	7 (12.7)	7 (13.0)	6 (10.7)	2 (3.7)	3 (5.6)	2 (3.8)
Injection site reaction	5 (9.1)	6 (11.1)	8 (14.3)	1 (1.9)	5 (9.3)	2 (3.8)
Back pain	4 (7.3)	8 (14.8)	6 (10.7)	5 (9.3)	5 (9.3)	3 (5.8)
Upper RTI	8 (14.5)	4 (7.4)	5 (8.9)	5 (9.3)	6 (11.1)	3 (5.8)
Pneumonia	4 (7.3)	3 (5.6)	9 (16.1)	2 (3.7)	2 (3.7)	4 (7.7)
Injection site erythema	2 (3.6)	3 (5.6)	9 (16.1)	1 (1.9)	4 (7.4)	1 (1.9)
Lower RTI	2 (3.6)	6 (11.1)	3 (5.4)	0	6 (11.1)	3 (5.8)
Headache	5 (9.1)	4 (7.4)	2 (3.6)	2 (3.7)	1 (1.9)	7 (13.5)
Injection site haematoma	0	5 (9.3)	6 (10.7)	2 (3.7)	0	0
RTI	6 (10.9)	4 (7.4)	0	2 (3.7)	1 (1.9)	3 (5.8)

Rhinitis	0	7 (13.0)	1 (1.8)	1 (1.9)	1 (1.9)	1 (1.9)
Decreased appetite	1 (1.8)	6 (11.1)	1 (1.8)	0	1 (1.9)	1 (1.9)
Patients with any treatment-related TEAE, n (%)	22 (40.0)	22 (40.7)	28 (50.0)	13 (24.1)	10 (18.5)	7 (13.5)
Patients with any SAE, n (%)	17 (30.9)	17 (31.5)	26 (46.4)	9 (16.7)	10 (18.5)	20 (38.5)
Most frequently reported SAEs,[¶] (%)						
IPF	7 (12.7)	7 (13.0)	14 (25.0)	3 (5.6)	2 (3.7)	8 (15.4)
Pneumonia	3 (5.5)	2 (3.7)	5 (8.9)	1 (1.9)	1 (1.9)	3 (5.8)
Bronchitis	1 (1.8)	0	0	0	0	2 (3.8)
Respiratory failure	0	0	0	0	0	2 (3.8)
Patients with any treatment-related SAE, n (%)	4 (7.3)	4 (7.4)	3 (5.4)	1 (1.9)	1 (1.9)	0
Patients with any TEAE leading to death, n (%)	7 (12.7)	3 (5.6)	6 (10.7)	4 (7.4)	3 (5.6)	7 (13.5)
Most frequently reported TEAEs leading to death,[¶] n (%)						
IPF	5 (9.1)	0	4 (7.1)	1 (1.9)	0	3 (5.8)
Patients with any TEAE leading to discontinuation, n (%)	8 (14.5)	9 (16.7)	12 (21.4)	7 (13.0)	4 (7.4)	11 (21.2)
Most frequently reported TEAEs leading to discontinuation,[¶] n (%)						
IPF						
Transient ischaemic attack	6 (10.9)	4 (7.4)	6 (10.7)	2 (3.7)	0	3 (5.8)
	0	0	0	0	2 (3.7)	0

[#]≥10% patients in any arm; [¶]>1 patient in any arm.

IPF: idiopathic pulmonary fibrosis; QW: once every week; Q2W: once every 2 weeks; RTI: respiratory tract infection; SAE: serious adverse event; TEAE: treatment-emergent adverse event.